CTA
AKBA icon

Carillon Tower Advisers’s Akebia Therapeutics AKBA Stock Holding History

Carillon Tower Advisers’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-2,060,804
Closed -$20.6M – 423
2018
Q2 		$20.6M Hold
2,060,804
– – 0.16% 211
2018
Q1 		$20.3M Hold
2,060,804
– – 0.16% 206
2017
Q4 		$30.6M Buy
+2,060,804
New +$34.2M 0.33% 110

Other funds holding AKBA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $5.48B AUM 3.63% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Carillon Tower Advisers's AKBA Position: Q3 2018 in Review

Carillon Tower Advisers sold out of Akebia Therapeutics (AKBA) in Q3 2018, closing a stake of 2,060,804 shares — an estimated $20.6M sold.

Carillon Tower Advisers first reported a position in AKBA in Q4 2017 and held it in 3 quarters. The position peaked at $30.6M in Q4 2017. 130 funds tracked by Wall St. Rank hold AKBA as of Q3 2018.

  • Carillon Tower Advisers reported no remaining Akebia Therapeutics position as of Q3 2018 after selling out during the quarter.
  • Carillon Tower Advisers sold 2,060,804 Akebia Therapeutics shares in Q3 2018, an estimated $20.6M.
  • Carillon Tower Advisers first reported a position in Akebia Therapeutics in Q4 2017 and held it in 3 quarters.
  • Carillon Tower Advisers's Akebia Therapeutics position peaked at $30.6M in Q4 2017.
  • 130 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q3 2018.

Based on Carillon Tower Advisers's 13F filing for Q3 2018, filed 13 Nov 2018.